This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

The future of the life sciences industries: Aftermath of the global recession

Deloitte Touche Tohmatsu & Economist Intelligence Unit announce survey results


DOWNLOAD  

The global recession has undoubtedly affected the life sciences industries - the question is whether the impact is temporary or more strategic and lasting? To assess the short- and long-term effects of the financial crisis, and to discover whether the downturn is just a difficult but not insurmountable event for life sciences companies—or if it's a turning point for the industry as whole, Deloitte Touche Tohmatsu Limited has collaborated with the Economist Intelligence Unit  to survey industry executives and leaders.

The findings are part of a new report, The future of the life sciences industries: aftermath of the global recession and was based on online surveys of 281 senior industry executives during Fall 2009. Of the respondents, 133 are board members or C-level executives. The report also draws on individual interviews with industry leaders. Their responses reveal that, while the immediate financial hit of the recession has been mostly absorbed, industry forces already in play will only be intensified by this most recent downturn and may permanently reshape the look of the industry.
Some key findings of the report include:

  • More than 65 percent of respondents indicated that their company has been moderately to significantly negatively affected by the recent global recession. A significant minority of 17 percent say that the recession will cause major changes to their pre-recession strategy.
  • 44 percent of respondents believe that 20 to 40 percent of existing biotech companies won't exist in five years as a result of the global recession. The equivalent figure for biotech executives surveyed was a more pessimistic 68 percent.
  • Companies that can sustain their focus on innovation will be the eventual "winners" in the industry. However, nearly one-third of respondents specify that their company is reducing R&D spend and 43 percent indicate that their company is focusing on products with immediate returns.

Download the full report below to learn more.

For more information, email us at dttlshc@deloitte.com.

Related Content

Stay connected

Stay connected:
Get connected
Share your comments

More on Deloitte
Learn about our site


Recently blogged